Medication Compatibility : Wegovy is compatible with gastric sleeve surgery for ongoing weight management
The Core GLP-1 Mechanism GLP-1 Pathway Simplified Meal Intake Intestinal L-cells release GLP-1 GLP-1 binds GLP-1 receptors cAMP signaling Activation of PKA + PI3K/Akt pathways Multiple metabolic benefits Practical Clinical Effects In the Pancreas Insulin secretion from -cells Glucagon secretion from -cells Preservation of -cell mass Reduced -cell apoptosis In the Brain Appetite suppression Satiety enhancement Reduced food cravings In the Gastrointestinal Tract Delayed gastric emptying Reduced postprandial glucose spikes In Peripheral Tissues Improved glucose uptake Enhanced insulin sensitivity Reduced hepatic gluconeogenesis Evolution of GLP-1 Therapy: Historical Milestones Current Era Emergence of: Oral GLP-1 drugs Dual agonists Triple agonists Small-molecule GLP-1 therapies Current GLP-1 Agents Short-Acting Exenatide Lixisenatide Long Acting Liraglutide Dulaglutide Semaglutide Oral GLP-1 Oral semaglutide Orforglipron (new generation oral small-molecule GLP-1RA) Dual Agonists Tirzepatide (GLP-1 + GIP) Triple Agonists Retatrutide (GLP-1 + GIP + glucagon receptor) These newer agents are redefining obesity medicine and cardiometabolic care
How Weight-Loss Drugs Escaped the Diabetes Clinic GLP-1 receptor agonists were developed and approved for type 2 diabetes, with obesity approval following only after trials like STEP and SURMOUNT showed consistent, significant weight loss details we cover in Part 1 on how these drugs work
The emotional impact of these changes shouldnt be overlooked
How retatrutide dosing compares to other GLP-1 peptides If you have experience with semaglutide or tirzepatide , you might assume retatrutide dosing follows a similar pattern
thus, currently available data do not provide sufficient evidence to support the clinical efficacy of aducanumab
